Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

BACKGROUND: The change in renal function induced by first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma remains unclear. METHODS: One hundred and thirty-four patients were evaluated. Sunitinib (SU) and sorafenib (SO) were administered to 91 (67.9%) and 43 (32.1%) patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishihara, Hiroki, Kondo, Tsunenori, Fukuda, Hironori, Yoshida, Kazuhiko, Omae, Kenji, Takagi, Toshio, Iizuka, Junpei, Kobayashi, Hirohito, Tanabe, Kazunari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896698/
https://www.ncbi.nlm.nih.gov/pubmed/29140528
http://dx.doi.org/10.1093/jjco/hyx161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896698/
https://www.ncbi.nlm.nih.gov/pubmed/29140528
http://dx.doi.org/10.1093/jjco/hyx161

Ejemplares similares